Haijiao Zhang

TL;DR: Analyses of samples from patients with acute myeloid leukaemia reveal that drug response is associated with mutational status and gene expression; the generated dataset provides a basis for future clinical and functional studies of this disease.

TL;DR: Exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, is performed to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondaryFLT3 mutations.

TL;DR: By integrating clinical characteristics, exome and RNA sequencing, and inhibitor data from primary AML patient samples, it is determined that myelomonocytic leukemia, upregulation of BCL2A1 and CLEC7A, as well as mutations of PTPN11 and KRAS conferred resistance to venetoclax and multiple venetClax combinations.

TL;DR: This work performed whole exome and RNA-sequencing of these rare hematologic malignancies and present the most complete survey of the genomic landscape of these diseases to date, finding a diversity of combinatorial mutational patterns that generally do not cluster within any one diagnosis.

TL;DR: This study investigated approximately 200 AML patient samples and correlated clinical parameters, whole exome sequence data, and RNAseq gene expression data with in vitro drug screening data to identify subsets of AML samples with sensitivity or resistance to venetoclax alone and in combinations with 10 small molecular inhibitors.